179 related articles for article (PubMed ID: 27659407)
1. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.
Tkáč I; Raz I
Diabetes Care; 2017 Feb; 40(2):284-286. PubMed ID: 27659407
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
3. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
4. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Raz I; Bhatt DL; Hirshberg B; Mosenzon O; Scirica BM; Umez-Eronini A; Im K; Stahre C; Buskila A; Iqbal N; Greenberger N; Lerch MM
Diabetes Care; 2014 Sep; 37(9):2435-41. PubMed ID: 24914244
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Jermendy G
Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
[TBL] [Abstract][Full Text] [Related]
7. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
8. An update on the 'gliptins'.
Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB; Bethel MA; Green JB; Stevens SR; Lokhnygina Y; Aschner P; Grado CR; Tankova T; Wainstein J; Josse R; Lachin JM; Engel SS; Patel K; Peterson ED; Holman RR;
Diabetes Care; 2017 Feb; 40(2):164-170. PubMed ID: 27630212
[TBL] [Abstract][Full Text] [Related]
10. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
Schernthaner G; Sattar N
J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
[No Abstract] [Full Text] [Related]
11. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Lin WQ; Cai ZJ; Chen T; Liu MB; Li N; Zheng B
Front Endocrinol (Lausanne); 2021; 12():684960. PubMed ID: 34484112
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
14. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
[TBL] [Abstract][Full Text] [Related]
16. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
Scheen A
Expert Opin Drug Saf; 2013 Jul; 12(4):545-57. PubMed ID: 23621381
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Effects of Incretin-Based Therapies.
White WB; Baker WL
Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
[TBL] [Abstract][Full Text] [Related]
18. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Scirica BM; Braunwald E; Raz I; Cavender MA; Morrow DA; Jarolim P; Udell JA; Mosenzon O; Im K; Umez-Eronini AA; Pollack PS; Hirshberg B; Frederich R; Lewis BS; McGuire DK; Davidson J; Steg PG; Bhatt DL;
Circulation; 2014 Oct; 130(18):1579-88. PubMed ID: 25189213
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin-induced recurrent acute pancreatitis.
Lee CF; Sun MS; Tai YK
Intern Med; 2014; 53(12):1351-4. PubMed ID: 24930656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]